by The tuberculosis vaccine market has been witnessing significant growth in recent years. Tuberculosis vaccines help in preventing tuberculosis by helping a person develop immunity to Mycobacterium tuberculosis. There are various types of tuberculosis vaccines available in the market, including Bacillus Calmette-Guérin (BCG) vaccine, recombinant BCG vaccine, and others. The BCG vaccine has been widely used for several decades. However, there is a need for more effective vaccines given the shortcomings of BCG. New vaccines based on recombinant DNA technology are being developed to provide long-lasting and improved protection against the disease.
The global tuberculosis vaccine market is estimated to be valued at US$ 172.42 billion in 2024 and is expected to exhibit a CAGR of 21% over the forecast period 2024 to 2030.
Key Takeaways
Key players operating in the tuberculosis vaccine market are Fujitsu Limited, Mindtree Limited, IBM Corporation, Wipro Limited, Unisys Corporation, CenturyLink Inc., Virtustream Inc. and HCL Technologies Limited. These players are focusing on developing new and improved vaccines through R&D and collaborations.
The market provides significant opportunities with the growing burden of tuberculosis globally and increasing government support for vaccine development. Many new vaccines are in various stages of clinical trials which can expand the treatment options if successful.
Advancements in recombinant DNA technology have enabled the development of new generation vaccines, which have the potential to provide lifelong or long-term protection with single or few doses. This includes vaccines based on viral vectors, recombinant BCG, and others which can help eliminate the disease.
Market drivers
The major driver for the Global Tuberculosis Vaccine Market Size is the high and growing incidence of tuberculosis cases worldwide. As per WHO, around 10 million people fell ill with tuberculosis in 2021. There is also an increasing focus on tuberculosis elimination programs by various governments and international organizations. The launch of new and more effective vaccines is expected to provide a boost to these elimination programs.
Current Challenges in Tuberculosis Vaccine Market:
Tuberculosis continues to remain a challenge to public health globally with millions affected by the disease every year. While there have been advancements in diagnosis and treatment, development of an effective vaccine against all strains of the pathogen remains a longstanding challenge. Existing vaccines offer limited and variable protection against adult pulmonary TB. Researchers are working to develop a more efficacious vaccine that provides lifelong and broad protection against all stages of TB infection and disease. However, vaccine development is a complex process requiring extensive clinical research and trials. Other challenges include the heterogeneity of TB strains worldwide, limited understanding of immune mechanisms, identification of reliable biomarkers and correlates of protection. Addressing these challenges would be critical to curbing the continued spread of this infectious disease.
SWOT Analysis
Strength: Existing BCG vaccine provides reasonable protection against severe forms of TB in children. Several vaccine candidates are in clinical trials with promising results in improving protection.
Weakness: BCG vaccine efficacy reduces with time and does not prevent reactivation of latent TB in adults. Reliable immune correlates of protection remain unknown, hampering vaccine development.
Opportunity: Significant global funding and research efforts towards developing new tools to combat TB. Understanding of TB immunology is improving with advances in scientific research methods.
Threats: Emergence of drug-resistant TB strains pose a serious threat to treatment and control efforts. Social determinants like poverty and malnutrition undermine TB prevention and management in many endemic regions.
Geographical Regions
In terms of value, the tuberculosis vaccine market remains concentrated in developing countries of Africa and South-East Asia which together account for over 80% of the global TB disease burden annually. Countries like India, China, Indonesia, Philippines, Pakistan and South Africa have a huge tuberculosis disease pool and vaccine sales are highest in these markets currently.
The Asia Pacific region is expected to see the fastest growth in the tuberculosis vaccine market during the forecast period. This is due to rising immunization programs, healthcare investments and economic development in highly populated countries of South Asia and South-East Asia where a majority of TB cases continue to arise each year. The increasing availability of new vaccine candidates currently in the pipeline would also likely boost regional market growth.
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
